VRBCF Stock Chart & Stats
$378.63
-$4.63(-1.21%)
―
--
Day’s Range― - ―
52-Week Range$340.60 - $473.86
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$3.34B
Enterprise Value$3.16K
Total Cash (Recent Filing)$122.50M
Total Debt (Recent Filing)$288.83M
Price to Earnings (P/E)18.6
Beta0.53
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.41%
Share Statistics
EPS (TTM)17.98
Shares Outstanding8,390,660
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio5.39
Price to Book (P/B)2.67
Price to Sales (P/S)2.05
P/FCF Ratio29.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$412.84Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)23.38
Revenue Forecast (FY)$1.77B
Bulls Say, Bears Say
Bulls Say
Revenue Growth AccelerationSustained and accelerating revenue through 2024–2025 signals durable demand across companion-animal and livestock segments. This supports longer-term topline resilience, funds product development and geographic expansion, and reduces dependency on short-term market swings.
Consistent Profitability And Strong ROEMid-teens ROE and ~10% net margins indicate high-quality earnings and efficient capital deployment. This persistent profitability underpins reinvestment capacity and strategic initiatives, supporting cash generation potential and long-run competitiveness in animal-health markets.
Conservative Balance Sheet With Expanding EquityLow-to-moderate leverage and rising equity provide financial flexibility for R&D, targeted M&A, or cyclical stress. A conservative capital structure reduces refinancing risk and preserves capacity to invest in manufacturing and regulatory approvals central to long-term animal-health growth.
Bears Say
Weaker Cash ConversionFCF falling to ~53% of net income highlights weaker cash conversion and potential working-capital or investment drains. Persistent below-par conversion can constrain organic reinvestment, dividend flexibility, and reduce buffer for strategic spending over the coming 2–6 months.
Margin Volatility And Slight CompressionVolatile gross margins and slight EBIT/EBITDA compression signal sensitivity to input costs, mix shifts, or pricing dynamics. This reduces earnings predictability and could limit sustainable margin improvement absent clearer cost control or pricing power improvements.
Uptick In Leverage Vs Prior LowsA rise in leverage from historically low levels shrinks financial headroom, increasing interest and refinancing exposure. Over a multi-month horizon this can limit strategic options (M&A, capex) and reduce resilience to adverse industry or regulatory shocks.
VRBCF FAQ
What was Virbac SA’s price range in the past 12 months?
Virbac SA lowest stock price was $340.60 and its highest was $473.86 in the past 12 months.
What is Virbac SA’s market cap?
Virbac SA’s market cap is $3.34B.
When is Virbac SA’s upcoming earnings report date?
Virbac SA’s upcoming earnings report date is Sep 17, 2026 which is in 55 days.
How were Virbac SA’s earnings last quarter?
Virbac SA released its earnings results on Mar 17, 2026. The company reported $9.307 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Virbac SA overvalued?
According to Wall Street analysts Virbac SA’s price is currently Undervalued.
Does Virbac SA pay dividends?
Virbac SA pays a Annually dividend of $1.66 which represents an annual dividend yield of 0.41%. See more information on Virbac SA dividends here
What is Virbac SA’s EPS estimate?
Virbac SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Virbac SA have?
Virbac SA has 8,390,660 shares outstanding.
What happened to Virbac SA’s price movement after its last earnings report?
Virbac SA reported an EPS of $9.307 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.98%.
Which hedge fund is a major shareholder of Virbac SA?
Currently, no hedge funds are holding shares in VRBCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Virbac SA
Founded in 1968 and based in Carros, France, Virbac S.A. is a prominent developer and distributor of a wide array of animal health products and services. The company's global operations extend across France, Europe, Latin America, North America, Asia Pacific, the Middle East, and Africa, catering to both domestic companion animals and commercial livestock. Its extensive portfolio encompasses vaccines, dental hygiene products, reproductive health solutions, dermatological treatments, parasiticides, diagnostic instruments, antibiotics, and aquaculture offerings. Furthermore, Virbac supplies specialized veterinary pharmaceuticals for anesthesia, geriatric care, behavioral management, and injectable micronutrients, alongside pet food and electronic identification systems. These diverse solutions are designed to support veterinarians, agricultural producers, and individual pet owners worldwide.
VRBCF Stock 12 Month Forecast
Average Price Target
$412.84
Ownership Overview
―
Insiders
6.97% Mutual Funds
― Other Institutional Investors
89.69% Public Companies and
Individual Investors